Microbial strain for preparing sitagliptin compound as well as preparation method and application of microbial strain

By developing a microbial strain Pseudomonasaeruginosa containing aminotransferase, using orthoxylene diamine dihydrochloric acid as an amino donor, the problems of expensive metal catalysts and low wild-type enzyme activity in sitagliptin synthesis in the prior art were solved, and high efficiency was achieved. Economical synthesis of sitagliptin.

CN118909842AActive Publication Date: 2024-11-08SUZHOU NORNS BIOTECHNOLOGY CO LTD +2
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410991789.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-08
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

In the existing sitagliptin synthesis method, metal catalysts are expensive and difficult to recover. In the enzyme catalytic method, wild-type aminotransferase cannot effectively catalyze chiral amino intermediates, resulting in difficulty in industrial production.

Method used

A microbial strain Pseudomonasaeruginosa containing aminotransferase was developed. Using orthoxylenediamine dihydrochloride as an amino donor, high-active microbial strains were screened through simple visualization methods to catalyze the synthesis of sitagliptin.

Benefits of technology

The synthesis of sitagliptin with high activity, good stereoselectivity and substrate tolerance has been achieved, which simplifies the catalytic process, reduces production costs, and has good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909842A_ABST
    Figure CN118909842A_ABST
Patent Text Reader

Abstract

The invention provides a microbial strain for preparing a sitagliptin compound as well as a preparation method and application of the microbial strain, and belongs to the technical field of bioengineering. The microbial strain for preparing the sitagliptin compound comprises a microbial strain containing transaminase, the microbial strain is preserved in the China Center for Type Culture Collection, the preservation address is Wuhan University, Wuhan, China, the preservation date is June 21, 2024, the preservation number is CCTCC NO: M20241336, and the Latin name is Pseudomonas aeruginosa. According to the method, a simple visual result analysis mode is used, a culture solution containing microbial thalli is used as a catalyst, the color of a reaction solution is observed, whether enzyme activity exists or not and the degree of the enzyme activity are rapidly judged, and a microbial strain containing transaminase is obtained through the method and can be used for catalytically producing a medicine sitagliptin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioengineering technology, and in particular to a microbial strain for preparing a sitagliptin compound, and a preparation method and application thereof. Background Art

[0002] Sitagliptin (MK-0431) is the first dipeptidyl peptidase-IV (DPP-IV) inhibitor approved by the US FDA for the treatment of type 2 diabetes. DPP-IV is a multifunctional enzyme that exists in the form of a homodimer on the cell membrane. It can cleave a variety of peptide hormones including incretins released in response to dietary intake, including glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1), both of which are closely related to type 2 diabetes. GLP-1 and GIP can increase insulin synthesis and release from pancreatic β cells through intracellular signaling pathways, reduce the secretion of glucagon by pancreatic α cells, and reduce hepatic glucose production. However, both GLP-1 and GIP are rapidly metabolized by DPP-4, resulting in the loss of their insulinotropic effects. Therefore, DPP-IV inhibitors reduce the degradation of the two by inhibiting DPP-IV, increase their concentrations in plasma, and thus improve postprandial blood sugar. In addition, sitagliptin increases insulin secretion in a blood sugar-dependent manner, has a moderate blood sugar-lowering effect, does not cause hypoglycemia, and has no side effects such as weight gain, nausea, and vomiting. It has been widely used and sold in recent years.

[0003] Most of the synthesis methods on the market currently require catalysts, which can be divided into two categories: metal-catalyzed synthesis and enzyme-catalyzed synthesis. As for the metal-catalyzed synthesis method, the metal catalysts used include ruthenium, platinum, palladium, etc. These catalysts are expensive, and it is also difficult to remove or recover these metal catalysts from the product; at the same time, the chiral purity of the chiral amino intermediates generated by the process using metal catalysts is not high enough, and further recrystallization and other methods are required to meet the requirements of the pharmacopoeia. The enzyme-catalyzed methods are all achieved by using ω-transaminase (ω-ATA), and they are all achieved through artificial modification of different wild-type transaminases. These enzymes provide amino donors, use sitagliptin precursor ketone as a substrate, and use pyridoxal phosphate (PLP) as a coenzyme to catalyze the generation of specific chiral sitagliptin. Compared with metal catalysts, enzyme-catalyzed synthesis of chiral amino intermediates has high stereoselectivity, the ee value of the transamination product can reach 99% or more, and the reaction conditions are mild. Public data shows that due to the special chemical structure of the chiral amino intermediate of sitagliptin, the wild-type transaminase existing in nature either cannot catalyze the synthesis reaction of the chiral amino intermediate or has very low catalytic activity and cannot be used for industrial production.

[0004] In the invention, through the use of an amine donor (o-xylylenediamine dihydrochloride), the donor has the dual function of effectively replacing the unfavorable reaction equilibrium to form a product, and at the same time provides a substrate-independent high-throughput colorimetric screening method to detect the activity of the desired transaminase-containing microbial strain. The present invention develops a transaminase-containing microorganism with high catalytic activity, good enantioselectivity, and good substrate tolerance, which can be used to catalyze the synthesis of aromatic isoindole, especially the catalytic synthesis of sitagliptin. Summary of the invention

[0005] In order to make up for the above deficiencies, the present invention provides a microbial strain for preparing sitagliptin compounds and a preparation method and application thereof, aiming to improve the deficiencies in the prior art.

[0006] The present invention is achieved in that: The present invention provides a microbial strain for preparing a sitagliptin compound, including a microbial strain containing a transaminase, wherein the microbial strain is deposited in the China Center for Type Culture Collection, the deposit address is Wuhan University, Wuhan, China, the deposit date is June 21, 2024, the deposit number is CCTCC NO: M20241336, and the Latin name is Pseudomonas aeruginosa.

[0007] A method for preparing a microbial strain for preparing a sitagliptin compound comprises the following steps: Step 1: Soil sampling and microbial isolation; Step 2: Cultivating the obtained microorganisms; Step 3: preparing mixed culture and crude enzyme solution; Step 4: Use the reaction system to screen the positive crude enzyme solution.

[0008] Preferably, the screening method for positive crude enzyme solution screening using the reaction system is as follows: Using o-xylylenediamine dihydrochloride as the amino donor for the catalytic reaction, the activity intensity is judged according to the depth of the color; The catalytic reaction includes a reaction system mother liquor and a crude enzyme solution, the volume of the reaction system mother liquor is 80-160 μL, and the crude enzyme solution and the reaction system mother liquor are mixed in equal volumes.

[0009] Preferably, the reaction system mother liquor comprises 0.1-0.3 mM tris(hydroxymethyl)aminomethane, a donor o-xylylenediamine dihydrochloride at a concentration of 4-12 g / L, a substrate sitagliptin precursor ketone at a concentration of 0.8-2.4 g / L, 0.1-0.3 mM coenzyme pyridoxal phosphate and a final concentration of 20% (v / v)-60% (v / v) of methanol, and the pH value of the reaction system mother liquor is 6.0-10.0.

[0010] An application of a microbial strain for preparing a sitagliptin compound, wherein the preparation method of the sitagliptin compound is as follows: Sitagliptin was prepared by adding crude enzyme solution using sitagliptin precursor ketone as substrate, methanol as cosolvent, pyridoxal phosphate as coenzyme, tris(hydroxymethylaminomethane) as buffer medium and isopropylamine as reaction system.

[0011] Preferably, the reaction solvent in the reaction system includes water, methanol, ethanol, propanol, isopropanol, isopropyl acetate, dimethyl sulfoxide or dimethylformamide.

[0012] Preferably, the conversion temperature in the reaction system is 20°C-50°C.

[0013] Preferably, the pH value in the reaction system is 6.0-10.0.

[0014] Preferably, the volume of the crude enzyme solution is 200-400 μL, the isopropylamine is 2-4 g / L, the concentration of tris(hydroxymethyl)aminoform is 0.1-0.2 mM, the concentration of the sitagliptin precursor ketone substrate is 0.4-0.8 g / L, the coenzyme pyridoxal phosphate is 0.1-0.2 mM, and the final concentration of methanol is 10-20%.

[0015] The beneficial effects of the present invention are: The present invention uses a simple visual result analysis method, uses a culture solution containing microbial cells as a catalyst, observes the color depth of the reaction solution, and quickly determines whether there is enzyme activity and the level of enzyme activity. Through this method, a microbial strain containing transaminase is obtained, which can be used for catalytic production of the drug sitagliptin and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0017] Figure 1 A reaction route for preparing sitagliptin using a microbial strain for preparing sitagliptin compounds provided in an embodiment of the present invention; Figure 2 This is a diagram showing the reaction results of a microbial strain for preparing a sitagliptin compound provided in an embodiment of the present invention, which can catalyze the transformation of sitagliptin into bacteria.

[0018] In the figure: 1. Sitagliptin precursor ketone; 2. Sitagliptin; 3. o-xylylenediamine dihydrochloride; 4. Cyclic imine; 5. Isoindole. DETAILED DESCRIPTION

[0019] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0020] Example 1: A microbial strain for preparing a sitagliptin compound, including a microbial strain containing a transaminase, wherein the microbial strain is deposited in the China Type Culture Collection, the deposit address is Wuhan University, Wuhan, China, the deposit date is June 21, 2024, the deposit number is CCTCC NO: M20241336, and the Latin name is Pseudomonas aeruginosa.

[0021] Embodiment 2: A method for preparing a microbial strain for preparing a sitagliptin compound, comprising the following steps: Step 1: Soil sampling and microbial isolation; Select an uncontaminated sampling site and dig 5-10 cm of soil below the surface; use sterile tools to collect soil samples and place them in sterile sampling bags or bottles; dry the soil samples and sieve them to remove large particles and debris; weigh 1 gram of soil sample, place it in a bottle containing 99 ml of sterile saline (0.85% NaCl), and shake vigorously for 5-10 minutes to obtain a soil suspension; Prepare a series of 10-fold dilution bottles, each containing 9 ml of sterile saline; add 1 ml of soil suspension to the first dilution bottle and mix thoroughly; add 1 ml of suspension from the first dilution bottle to the second dilution bottle, and repeat this process until the desired dilution multiple is reached; Prepare culture media suitable for the growth of different microorganisms; the purpose of selecting culture media with different nutritional components is to obtain as many different types of microorganisms as possible, that is, to obtain microorganisms containing transaminase as possible; the components of various culture media are as follows: Medium No. 1. **Nutrient Agar** - Beef extract: 3 g - Peptone: 5 g - Sodium chloride: 5 g - Agar: 15 g - Distilled water: 1000 ml - Adjust pH to 7.0-7.2 Medium 2. **Potato Dextrose Agar (PDA)** - Potatoes: 200 g (cooked and filtered) - Glucose: 20 g - Agar: 15-20 g - Distilled water: 1000 ml - Adjust pH to 5.6 (suitable for fungi) Medium No. 3. **Sabouraud Dextrose Agar (SDA)** - Glucose: 40 g - Trypticase: 10 g - Agar: 15-20 g - Distilled water: 1000 ml - Adjust pH to 5.6 (suitable for fungi) Medium No. 4. **MacConkey Agar** - Trypticase: 17 g - Tryptone: 3 g - Bile salt mixture: 1.5 g - Sodium chloride: 5 g - Lactose: 10 g - Neutral red: 0.03 g - Evening red: 0.001 g - Agar: 13.5 g - Distilled water: 1000 ml - pH adjusted to 7.1 (selective cultivation of intestinal bacteria) Medium No. 5. **Mannitol Salt Agar** - Tryptone: 10 g - Beef extract: 1 g - Sodium chloride: 75 g - Mannitol: 10 g - Benzene red: 0.025 g - Agar: 15 g - Distilled water: 1000 ml - Adjust pH to 7.4 (selective cultivation of salt-tolerant bacteria) Take 0.1 ml of soil suspension of different dilutions and evenly spread it on the corresponding culture medium plate; inoculate at least three plates for each dilution to ensure the reliability of the results; invert the plate and culture at 37°C for 24 to 48 hours to obtain colonies of different shapes, colors and sizes; pick up a single colony with a sterile inoculation loop and inoculate it on a new culture medium plate for purification and culture; repeat the purification process until a pure strain is obtained; Step 2: Cultivating the obtained microorganisms; After the above-mentioned cultivation is completed, the microorganisms obtained from different culture medium plates are mixed and cultured in liquid culture medium with the same components, and 10 single colonies are inoculated as a 96-well deep-well plate culture unit; Step 3: preparing mixed culture and crude enzyme solution; The detailed steps for bacterial culture in 96-well plates, cell harvesting, and cell lysis with lysozyme to release the enzyme solution are as follows: Bacteria are inoculated into a 96-well deep-well plate containing culture medium; 200-300 µL of culture medium is usually added to each well; the deep-well plate is placed in a shaker incubator set to 25 degrees Celsius; the shaker speed is adjusted to 250 rpm to ensure adequate gas exchange in the culture medium; the culture is usually incubated for 18-36 hours until the culture medium becomes turbid, indicating that the bacteria have fully grown; Centrifuge the 96-well deep-well plate at 4000-5000 g for 10-15 minutes to pellet the bacterial cells; After centrifugation, carefully remove the supernatant, trying to avoid disturbing the pelleted bacterial cells; Add an appropriate amount of lysozyme-containing buffer solution to each well, 50-100 µL per well; the concentration of lysozyme is generally 1 mg / mL, 50-100 µL per well; Place the 96-well plate on ice for 15-30 minutes to allow lysozyme to act on the cell wall; Then, place the 96-well plate in a 37°C water bath or incubator and gently shake it to further promote cell lysis for 30 minutes; Finally, the lysed mixture is centrifuged again to separate the soluble components in the supernatant, which are the released enzyme solution; Centrifuge at 12,000-14,000 rpm at 4 degrees Celsius for 10-15 minutes to pellet insoluble cell debris; Carefully remove the supernatant, which is the solution containing the target enzyme to be screened; Step 4: Screening positive crude enzyme solution using the reaction system; Prepare the reaction system mother solution (prepared and used immediately): 0.1 mM tris(hydroxymethyl)aminomethane as the buffer medium, the donor o-xylylenediamine dihydrochloride concentration is 4 g / L, the substrate sitagliptin precursor ketone concentration is 0.8 g / L, the coenzyme PLP is 0.2 mM, the methanol concentration is 40% (v / v), and the pH is 8.5; The target enzyme solution prepared in step 3 is directly used for screening reaction; 80 μL crude enzyme solution and 80 μL reaction mother solution are added to a 96-well reaction plate, and the reaction is carried out in a shaker at 45°C and 200 rpm. After 60 minutes, the color change is observed and analyzed; Collect and count the wells of the well plate that have changed color, and select the top 5 wells with the darkest color for rescreening confirmation and strain tracing; Examples 3 to 7 are respectively methods for preparing a microbial strain for preparing a sitagliptin compound. The operation steps are the same as those of Example 2, except that the volume of the mother solution and the crude enzyme solution of the reaction system, the culture time, the culture temperature, the centrifugal speed and other parameters are different, as shown in the following table:

[0022] Rescreening method: The suspected target enzyme solution that has developed color was diluted to one-half and one-quarter of the original concentration. Under the same reaction system and conditions, three parallel rescreenings were performed in each group. The final color development was as follows: Figure 2 As shown ( Figure 2 The color development shown in is the color development result produced by the self-polymerization of isoindole). The results show that the degree of color development increases with the increase of catalytic enzyme activity, thus confirming that the microorganism is very likely to contain the transaminase required for catalyzing the production of sitagliptin.

[0023] Example 8: Application of a microbial strain for preparing a sitagliptin compound. The preparation method of the sitagliptin compound is as follows: Sitagliptin is prepared by adding crude enzyme solution using sitagliptin precursor ketone as substrate, methanol as cosolvent, pyridoxal phosphate as coenzyme, and tris(hydroxymethyl)aminomethane as buffer medium as reaction system; the reaction solvent in the reaction system includes water, methanol, ethanol, propanol, isopropanol, isopropyl acetate, dimethyl sulfoxide or dimethylformamide, as shown in Figure 1(In the figure: 1 is sitagliptin precursor ketone; 2 is sitagliptin; 3 is o-xylylenediamine dihydrochloride; 4 is cyclic imine; 5 is isoindole; the reaction process is that sitagliptin precursor ketone is catalyzed and converted into sitagliptin by a microbial strain containing transaminase with a deposit number of CCTCC NO: M20241336; and in this process, o-xylylenediamine dihydrochloride is catalyzed and converted into sitagliptin by a microbial strain containing transaminase with a deposit number of CCTCC NO: M20241336. NO: M20241336 is used as a microbial strain containing a transaminase to generate benzaldehyde o-imine hydrochloride and HCl under the catalytic conversion. The generated benzaldehyde o-imine hydrochloride then undergoes a self-cyclization reaction to generate a cyclic imine (it should be noted that the generated benzaldehyde o-imine hydrochloride has a very short existence time and will quickly undergo a self-cyclization reaction to generate a cyclic imine, and the generated benzaldehyde o-imine hydrochloride is a transition state of the cyclic imine). The cyclic imine undergoes tautomerism to generate isoindole, and the isoindole itself undergoes a polymerization reaction to generate a black precipitate, namely Figure 2 ); The target crude enzyme solution prepared in step 4 is used to carry out a catalytic reaction of the target molecule; the reaction system is: 200 μL of the target crude enzyme solution, 2 g / L of isopropylamine, 0.1 mM of tris(hydroxymethyl)aminoformate, 0.4 g / L of substrate sitagliptin precursor ketone, 0.1 mM pyridoxal phosphate, 10% methanol final concentration, and pH 8.5 of the reaction solution; after 24 hours of conversion at 20°C, after the reaction is completed, acetonitrile of the same volume as the reaction system after the conversion reaction is added for inactivation, and then centrifuged (4000 rpm, 30 min), the supernatant after centrifugation is taken, and high performance liquid chromatography analysis is performed according to the following analytical method to calculate the conversion rate of the substrate to the product; after calculation, the target crude enzyme solution achieves a substrate conversion rate of more than 95% in 24 hours, indicating that the transaminase produced by the strain can effectively realize the catalytic reaction of sitagliptin precursor ketone to sitagliptin.

[0024] Examples 9 to 13 are respectively applications of a microbial strain for preparing a sitagliptin compound, and the operation steps are the same as those of Example 8, except that the volume of the crude enzyme solution, the concentrations of sitagliptin precursor ketone, methanol, pyridoxal phosphate, tris(hydroxymethyl)aminomethane and isopropylamine, the conversion time, the conversion temperature, the centrifugation speed, the centrifugation time and other parameters are different, as shown in the following table:

[0025] The analysis method is a high performance liquid chromatography, and the conditions are: the chromatographic column is Agilent Eclipse XDB-C8 (4.6 X150mm / 5 microns), the eluent is 10mM NH4Ac / MeCN, the flow rate is 1.5ml / min, and the column temperature is 40 degrees Celsius. Retention time: 1.7 minutes for ketoamide substrate and 1.4 minutes for sitagliptin. The ketoamide substrate and product in the eluate are determined as the peak area at 210nm or 286nm.

[0026] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A microbial strain for preparing a sitagliptin compound, characterized in that: It includes a microbial strain containing transaminase, which is deposited in the China Type Culture Collection Center, the deposit address is Wuhan University, Wuhan, China, the deposit date is June 21, 2024, the deposit number is CCTCC NO: M20241336, and the Latin name is Pseudomonas aeruginosa.

2. A method for preparing a microbial strain for preparing a sitagliptin compound, applied to the microbial strain for preparing a sitagliptin compound according to claim 1, characterized in that: The steps include: Step 1: Soil sampling and microbial isolation; Step 2: Cultivating the obtained microorganisms; Step 3: preparing mixed culture and crude enzyme solution; Step 4: Use the reaction system to screen the positive crude enzyme solution.

3. The method for preparing a microbial strain for preparing a sitagliptin compound according to claim 2, characterized in that: The screening method for positive crude enzyme solution screening using the reaction system is as follows: Using o-xylylenediamine dihydrochloride as the amino donor for the catalytic reaction, the activity intensity is judged according to the depth of the color; The catalytic reaction includes a reaction system mother liquor and a crude enzyme solution, the volume of the reaction system mother liquor is 80-160 μL, and the crude enzyme solution and the reaction system mother liquor are mixed in equal volumes.

4. The method for preparing a microbial strain for preparing a sitagliptin compound according to claim 3, characterized in that: The mother liquor of the reaction system comprises 0.1-0.3 mM tris(hydroxymethyl)aminomethane, a donor o-xylylenediamine dihydrochloride with a concentration of 4-12 g / L, a substrate sitagliptin precursor ketone with a concentration of 0.8-2.4 g / L, 0.1-0.3 mM coenzyme pyridoxal phosphate and methanol with a final concentration of 20% (v / v)-60% (v / v), and the pH value of the mother liquor of the reaction system is 6.0-10.

0.

5. An application of a microbial strain for preparing a sitagliptin compound, using the microbial strain for preparing a sitagliptin compound according to claim 1, characterized in that: The preparation method of the sitagliptin compound is as follows: Sitagliptin was prepared by adding crude enzyme solution using sitagliptin precursor ketone as substrate, methanol as cosolvent, pyridoxal phosphate as coenzyme, tris(hydroxymethylaminomethane) as buffer medium and isopropylamine as reaction system.

6. The use of a microbial strain for preparing a sitagliptin compound according to claim 5, characterized in that: The reaction solvent in the reaction system includes water, methanol, ethanol, propanol, isopropanol, isopropyl acetate, dimethyl sulfoxide or dimethylformamide.

7. The use of a microbial strain for preparing a sitagliptin compound according to claim 5, characterized in that: The conversion temperature in the reaction system is 20°C-50°C.

8. The use of a microbial strain for preparing a sitagliptin compound according to claim 5, characterized in that: The pH value in the reaction system is 6.0-10.

0.

9. The use of a microbial strain for preparing a sitagliptin compound according to claim 5, characterized in that: The volume of the crude enzyme solution is 200-400 μL, the isopropylamine is 2-4 g / L, the concentration of tris(hydroxymethyl)aminoform is 0.1-0.2 mM, the concentration of the sitagliptin precursor ketone substrate is 0.4-0.8 g / L, the coenzyme pyridoxal phosphate is 0.1-0.2 mM, and the final concentration of methanol is 10-20%.

Citation Information

Patent Citations

  • Pseudomonas pseudoalcaligenes and application of pseudomonas pseudoalcaligenes to preparation of sitagliptin intermediate

    CN105274027A

  • Pseudomonas aeruginosa ZJPH1504 and application thereof in preparation of sitagliptin chiral intermediate

    CN105925506A

  • Omega-transaminase from bacillus pumilus and application in biological amination

    CN109402188A

  • Engineered transaminase polypeptides

    US20210317421A1